Genetically modified stem and progenitor cells have emerged as a promising regenerative platform in the treatment of genetic and degenerative disorders, highlighted by their successful therapeutic use in inherent immunodeficiencies. However, biosafety concerns over insertional mutagenesis resulting from integrating recombinant viral vectors have overshadowed the widespread clinical applications of genetically modified stem cells. Here, we report an RNA-based episomal vector system, amenable for longterm transgene expression in stem cells. Specifically, we used a unique intranuclear RNA virus, borna disease virus (BDV), as the gene transfer vehicle, capable of persistent infections in various cell types. BDV-based vectors allowed for long-term transgene expression in mesenchymal stem cells (MSCs) without affecting cellular morphology, cell surface CD105 expression or the adipogenicity of MSCs. Similarly, replication-defective BDV vectors achieved long-term transduction of human induced pluripotent stem cells, while maintaining the ability to differentiate into three embryonic germ layers. Thus, the BDV-based vectors offer a genomic modification-free, episomal RNA delivery system for sustained stem cell transduction.
INTRODUCTION
Genetically modified stem and progenitor cells can provide powerful tools to treat genetic and degenerative disorders. To date, integrating retro-or lentiviral vectors has been extensively used for sustained genetic modification. For instance, in X-linked severe combined immunodeficiency (X-SCID) gene therapy trials, patients with X-SCID received hematopoietic stem cells transduced with retroviral vectors to express the common γ-chain from IL2RG. [1] [2] [3] Although these trials demonstrated successful therapy for X-SCID, [3] [4] [5] [6] a subset of the treated patients subsequently developed leukemia due to the activation of host oncogenes by integrated retroviral sequences, that is, insertional mutagenesis, 1, 7 illustrating a biosafety concern of integrating vectors. Various non-integrating DNA transfer platforms, such as adenoviral or adeno-associated viral vectors, are currently available. However, these vectors typically achieve transient transgene expression and, in general, cannot support long-term genetic modification in rapidly proliferating cells. 8 Borna disease virus (BDV) is a non-segmented, negative-strand RNA virus with a broad host range. 9 BDV causes neuronal disorders in horses, sheep, cats and cattle. 9, 10 In humans, BDV infection has been linked to various neurological disorders, such as major depressive disorder, bipolar disorder and schizophrenia. However, a recent multicenter study, with standardized methods for clinical assessment and blinded to serological and molecular analysis of 396 subjects (198 matched controls), found no BDV sequences in any samples. The study did report a 2% immunoreactivity to BDV (8 of 396); however, there was no link found between BDV sero-positivity and neurological disorders. 11 This observation, among others, strongly suggests no relationship between BDV and the pathogenesis of human psychiatric disorders. Although a novel variegated squirrel bornavirus was recently identified and linked to fatal human encephalitis cases in Germany, variegated squirrel bornavirus is different from well-characterized BDV strains. 12 BDV has unique biological properties as an RNA virus, such as intranuclear replication and transcription, 13, 14 along with employing splicing, in order to express overlapping open reading frames. [15] [16] [17] Our recent study has revealed that the BDV ribonucleoprotein interacts directly with the host chromosome using core histones as a docking platform throughout the cell cycle, facilitating persistent intranuclear BDV infection. 18 Additionally, BDV replication is not lytic and extremely slow, supporting persistent infection in the nervous system 19 or peripheral blood mononuclear and bone marrow cells. 20 These biological characteristics are ideal for a non-integrating vector system capable of sustained transgene expression. Staeheli and colleagues 21 have established a prototypic BDV-based gene transfer vector system, which encodes an expression cassette for green fluorescent protein (GFP) at a site near the 5′ end of the BDV genome. Recently, we have developed both replicationcompetent and replication-defective BDV vector systems, allowing transgene expression from an intercistronic non-coding region. 22 Like wild-type BDV, BDV-based vectors also replicate intranuclearly, evident by intranuclear viral speckle of transcripts (vSPOTs), 18, 22 facilitating sustained transgene expression in cultured cells as well as in neurons. [21] [22] [23] In this study, we employed replication-competent BDV and M and G proteins-deleted replication-defective BDV vectors in order to genetically modify two stem cell types: mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs). Our results demonstrate long-term transgene expression in MSCs and iPSCs without impairing their differentiation potential.
RESULTS

Infection of cells from different species with recombinant BDV vectors
We first assessed the infectivity of our replication-defective BDV vector with deletion in the G protein, rBDV ΔMGP/M-GFP, on various cell lines at a multiplicity of infection of 0.05 (determined in Vero cells). BDV vectors infected all cell lines tested, with some variation in transduction efficiency. One week post infection, GFP-positive cell populations were analyzed by flow cytometry (Figure 1a ). Human neuronal U251 cells and canine renal D17 cells were particularly susceptible to the rBDV ΔMGP/M-GFP vector. Similar results were observed with our replication-competent recombinant BDV, rBDV P/M-GFP (not shown). As reported previously, rBDV ΔMGP/M-GFP vector-infected cells remained GFP-positive 2 months post infection, indicating sustained transduction of various cell types (Figure 1b) . Similarly, GFPpositive cells were found in cells infected by replicationcompetent rBDV P/M-GFP virus, although expanded GFP signals were found only in select cell lines, such as 293 T, U251, Vero, D17, DK and CRFK cells ( Figure 1b ). Intriguingly, when cell-free BDV stockswere prepared from these cell lines, as described in the Materials and methods section, only Vero and DK cells showed over 10 5 infectious units (IU) ml − 1 of BDV titers, while less than 10 3 IU ml − 1 of cell-free BDV were produced from 293 T, U251, D17 and CRFK cells. Thus, although various cell types from a range of species are permissive to persistent BDV infection, select cell lines appear to support efficient BDV production.
BDV vectors achieve long-term transgene expression in MSCs without affecting their adipogenic potential Adipose-derived MSCs were first analyzed for their expression of major MSC markers. Flow cytometry analysis verified high levels of expression of CD44, CD90 and CD105 (Figure 2a ). When MSCs were infected with cell-free recombinant BDV vector, rBDV P/M-GFP, at a multiplicity of infection of 0.1, approximately 10% of cells became GFP-positive 1 week after infection. The GFP-positive cell population had increased to 480% positive at 6 weeks post infection ( Figure 2b ). Importantly, BDV vector infection showed no notable effect on the growth or morphology of infected MSCs, with surface CD105 expression unchanged in BDV-infected GFP-positive cells (Figure 2c ).
To assess the influence of BDV vector infection on the differentiation capacity of MSCs, we cultured MSCs infected with rBDV P/M-GFP for 6 weeks in adipogenesis differentiation medium. One week after differentiation, formation of small lipid droplets was evident in infected and uninfected MSCs. Two weeks of adipogenic differentiation resulted in the generation of adipocytes with numerous large lipid droplets, confirmed by Oil Red O staining ( Figure 2d ). Importantly, BDV-infected cells remained GFP positive throughout the differentiation, and BDV infection did not impair the adipogenic potential of MSCs ( Figure 2d ).
BDV vectors efficiently transduce human iPSCs but not mouse iPSCs Next, we assessed the permissivity of mouse and human iPSCs to BDV vector transduction. For this, we used our replicationdefective recombinant BDV vector with deletion in the G protein (rBDV ΔMGP/M-GFP). To achieve more efficient BDV vector transduction we cocultured rBDV ΔMGP/M-GFP vector-producing cells with iPSCs. Specifically, dissociated mouse and human iPSCs were seeded on a cell-cycle-arrested BDV vector producer cell line, pretreated by mitomycin C. Co-cultivation of mouse iPSCs with BDV producer cells did not lead to the generation of GFP-positive iPSCs, even after prolonged co-cultivation and passaging, suggesting that mouse iPSCs are resistant to BDV vector transduction ( Figure 3a ). In contrast, GFP-positive human iPSCs appeared as early as 4 days post co-cultivation ( Figure 3a ). Through serial passaging, rBDV ΔMGP/M-GFP-infected human iPSCs, with stable GFP expression, were successfully expanded ( Figure 3b ). Flow cytometry analysis revealed GFP-positive iPSC population at 2 and 6 weeks post co-cultivation as 29.6 and 21.2%, respectively. Similarly, human iPSCs were permissive to a replication-competent GFP-expressing BDV vector (Figure 3b , right panels). Four weeks after infection with cell-free rBDV P/M-GFP at multiplicity of infection of 0.1, 36.6% of human iPSCs were GFP positive. BDV vector infection did not affect the growth or the morphology of infected cells, and rBDV ΔMGP/M-GFP-infected human iPSCs showed comparable expression levels of pluripotency-associated factors, including OCT4, SOX2, SSEA4 and TRA-1-60 ( Figure 3c ).
BDV vector-infected human iPSCs maintain pluripotency
To assess the influence of BDV vector infection on the pluripotency of iPSCs, uninfected and BDV vector-infected cells were allowed to form embryoid bodies ( Figure 4a ). Further spontaneous differentiation in vitro resulted in the generation of cells from all three germ layers, including βIII-tubulin-positive neuronal cells (ectoderm), FOXA2-positive endoderm, CD31/PECAM1-positive endothelial cells (mesoderm) and cardiac troponin-positive cardiomyocyte (mesoderm), with no notable difference between control and BDV-infected human iPSCs (Figure 4b ). To assess the long-term BDV infection on the differentiation propensity of iPSCs, BDV-infected human iPSCs were further cultured for 4 months, and the percent GFP-positive cell populations were determined by flow cytometry (Figure 4c ). Nearly 100% of iPSCs became GFP positive, indicating long-term persistent infection of BDV virus in human iPSCs (Figure 4c , lower panels). Upon guided differentiation into definitive endoderm cells, the BDV-GFP virus-infected cells showed over 100-fold induction of definitive endoderm markers (FOXA2 and SOX17 transcripts), comparable to those of control iPSCs (Figure 4d ). These observations demonstrated the utility of BDV vectors for sustained iPSC modification without affecting the pluripotency.
DISCUSSION
Integrating retro-and lentiviral vectors has been extensively used for stem cell gene therapy trials. Recent trials using self-inactivating lentiviral vectors have demonstrated promising tumor-free therapy. [24] [25] [26] Nevertheless, the biosafety concern over vectormediated insertional mutagenesis still remains a major challenge for stable stem cell modification, as self-inactivating lentiviral vectors have been shown to induce leukemia in a mouse model of X-SCID. 27, 28 In this context, recent advances in site-directed gene editing technologies, including Zinc finger nucleases, 29 TALE nuclease 30 and CRISPR systems, 31 are notable, as they allow genetic modification without random integration. At present, however, these site-directed gene editing technologies are relatively inefficient and still entertain risks of off-target cleavage, presenting a formidable barrier in any immediate clinical applications. Additionally, screening stem and progenitor cells with correct gene edits typically requires expansion and screening of single cell clones, which is not feasible for many stem and progenitor cell types. It should be noted that prolonged ex vivo culturing and expansion of stem and progenitor cells often leads to impaired differentiation and decreased repopulation efficiency. 32 Here, we demonstrated that the BDV vector system facilitates sustained transgene expression in MSCs and iPSCs without affecting their proliferation or differentiation capacity. Importantly, the BDV vector system has biological properties highly attractive for stem cell modification: (i) BDV achieves persistent intranuclear infection through close association with host chromosomes throughout the cell cycle, 18 (ii) BDV persistently infects neural stem/progenitor cells, 33 (iii) BDV G protein plays a critical role in the release of infectious BDV particles allowing for the generation of replication-and particle-release-free BDV vectors through the G protein deletion, 22 and (iv) BDV vectors show long-term transgene delivery in vivo without notable toxicity. 22 Thus, the BDV vector system offers a promising non-integrating RNAbased platform for sustained stem cell modification.
Currently, a major limitation of the BDV vector system is the difficulty in obtaining high infectious titer vector stocks. After purification, BDV vector titers typically reach 10 5 to 10 6 IU ml − 1 . The titers are comparable to those of unconcentrated gammaretroviral vectors, but not comparable to VSV-G-pseudotyped lentiviral vectors, which can reach 10 10 IU ml − 1 after concentration by ultracentrifugation. Like low titer retroviral vectors, introduction of an antibiotic resistant gene into BDV vectors would allow selection of transduced cells. Since additional genes would increase the vector genome size, further studies are required to define the packaging capacity of BDV. BDV has an 8.9 kb genome, which is relatively short for an RNA virus. Our preliminary data have demonstrated successful generation of a BDV vector carrying the 1.6 kb luciferase gene. Accordingly, the BDV vector should be able to accommodate at least a 10.5 kb genome. Removal of non-essential viral genes, such as the G and M protein genes, will further increase the packaging capacity of BDV vectors. Another limitation is the possible influence of persistent BDV infection on cellular functions. For instance, BDV-P protein has been shown to interact with multifunctional protein, HMGB1, and inhibits its function in cultured neural cells. 34 The BDV-P interaction with HMGB1 also blocks the tumor suppressor p53 or p53-mediated activation of the major senescence-inducing factor p21. 35 Although BDV infection induces no or low levels of interferon, due to post-transcriptional removal of the RIG-I-activating RNA 5′ triphosphate group 36 and BDV-X protein interfering with the type 1 IFN signaling, 37 long-term, persistent BDV vector infection may also affect normal cellular functions through activation of interferon-stimulated genes. Thus, further studies are necessary to elucidate the influence of sustained BDV infection on stem cell fates or functionality of stem cell-derived cell products.
A potential issue is the BDV integration into the host genome. This concern is based on our recent reports on identification of endogenized bornavirus-related elements from ancient bornaviruses in mammalian genomes. 38, 39 However, this concern is not specific to BDV vectors. We have shown that integrated bornavirus-related sequences have poly-A tails and target site duplications, suggesting that ancient bornavirus-integration events were mediated by non-specific mRNA reverse transcription and integrations by LINE-1 (long interspersed nuclear element-1), a non-LTR retrotransposon. 39, 40 In theory, LINE-1-mediated integration can occur for any RNA viruses and cellular transcripts. Indeed, similar fossilized RNA viral elements from ebolavirus/ marburgvirus and tamana bat virus, and various poly-A tailed cellular transcripts-like DNA sequences, have been found in vertebrate genomes. [40] [41] [42] Thus, bornaviral integration process is not particularly efficient, likely because the process requires both reverse transcription and integration by non-specific interaction with LINE-1 components. 42, 43 Recently, we have demonstrated that the integration of BDV or rBDV vector sequences is rare. Even when over 90% of cells persistently infected by BDV for 8 weeks, we found 0 and 0-0.007 copies per cell of BDV-specific DNA sequences in 293 T and human oligodendroglioma OL cells, respectively. 43 Clearly, this is in sharp contrast to other integrating vectors, which are based on retro-or lenti-viruses.
In relation to low BDV vector titers, we also noticed that BDV vector infection of certain cell lines was strongly inhibited at higher vector doses. For instance, when U251 and NP2 cell lines were infected by GFP-expressing BDV at multiplicity of infection 0.1 and 0.5 (standardized in Vero cells), the GFP-positive cell populations were 39.1 and 5.5% for U251 and 4.1 and 2.0% for NP2 cells, respectively. Similar findings have been reported with lentiviral vectors pseudotyped with amphotropic murine leukemia virus-A Env, largely due to high levels of dissociated particle-free murine leukemia virus-A Env protein in the vector preps competing with infectious vector particles. 44 VSV-G-pseudotyped vectors do not show this phenotype because of the stability of VSV-G and its ubiquitous receptor, facilitating efficient vector infection. It is plausible that BDV vector preps contain high levels of particle-free BDV G protein, or defective BDV vector particles, which antagonize the interaction between infectious BDV vector particles and functional entry receptors on target cells. It is also conceivable that BDV uses an entry receptor that is not abundant at least in U251 and NP2 cells. The use of a gel-filtration column to remove excessive particle-free BDV G protein during vector purification may improve the problematic, low vector infectivity at high vector doses. Alternatively, incorporation of a heterologous viral glycoprotein, such as a modified VSV-G, 22 for pseudotyped BDV vectors, would allow production of higher titer vectors with improved infectivity and stability.
For validating the safety of gene transfer vectors, as well as the feasibility of gene therapy strategies, it is critical to have a relevant small animal model. Ideally, BDV vectors would transduce both human and preclinical animal models equally well. Unfortunately, we found that BDV vectors failed to transduce mouse iPSCs. Since no BDV-infected cell was found after several attempts, it is conceivable that mouse iPSCs do not express a functional BDV receptor. It is also notable that mice and mouse-derived cells are generally more resistant to BDV infection. 45 Previous studies have established replicating mouse-adapted BDV strains through serial passaging of BDV in rat brains, 45, 46 resulting in two amino acid substitutions, R66K and L116R in the P and L proteins. 46 Notably, Ackermann et al. 23 developed a GFP-carrying, mouse-adapted BDV, facilitating viral dissemination in the mouse nervous system. We are currently in the process of generating a replicationdefective BDV vector system with R66K and L116R mutations for an improved BDV vector mouse-system.
In conclusion, our data demonstrate sustained transgene expression in human MSCs and iPSCs by BDV vectors. Our preliminary study also showed human CD34+ cells are permissive to BDV infection (Supplementary Figure S1 ). Although further improvements in increased vector titers are necessary, the BDVbased vectors offer a unique episomal RNA delivery platform for sustained stem cell modification without genomic modification.
MATERIALS AND METHODS
All studies were approved by Mayo Clinic Institutional Biosafety Committee.
Cells Human U251, 293 T and PANC1 cells, rhesus monkey FrhK4 cells, African Green Monkey Vero and CV1 cells, Dog D17 and DK cells, mouse Min6 cells, feline CRFK cells, bovine MDBK cells and rat NRK cells were grown in
Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics as described previously. 47 Mouse iPSCs were generated from murine fibroblasts by lentiviral transduction of four reprogramming factors 48 and cultured without feeder cells on Matrigelcoated plates (BD Biosciences, San Jose, CA, USA) in ESGRO-2i medium (EMD Millipore, Billerica, MA, USA) supplemented with 45% Dulbecco's modified Eagle's medium, 5% fetal calf serum, 25 Uml − 1 penicillin and 25 μg ml − 1 streptomycin. Transgene-free iPSCs were reported previously, 49 which were cultured in Pluriton medium (Stemgent, Cambridge, MA, USA) supplemented with 25% mTeSR1 medium (Stemcell Technology) and 50 U ml − 1 penicillin and 50 μg ml − 1 streptomycin. Adipose-derived MSCs were derived and cultured as described previously. 50 
BDV vectors
A replication-competent, recombinant BDV vector harboring a GFP gene in the intercistronic region between the P and M genes (rBDV P/M-GFP), and a replication-defective BDV vector with deletion in the BDV M and G genes (rBDV ΔMGP/M-GFP) were reported previously. 22 Briefly, the replicationcompetent recombinant BDV vector was rescued in 293 T cells transfected with BDV vector plasmid, pCA-N, pCXN2-P and pCA-L, 51 or with additional pBDV-G for the ΔMGP/M vector, 22 followed by co-culturing of the cells with Vero or Vero-BG cells. 22 rBDV P/M-GFP and rBDV ΔMGP/M-GFP vectors were expanded in Vero cells and BDV M and G protein-expressing Vero cells, respectively. For preparation of cell-free BDV vectors, 100% confluent BDV producer cells in 6 × 10 cm dishes were harvested and resuspended in 1.2 ml of Dulbecco's modified Eagle's medium medium supplemented with fetal calf serum, sonicated by BioRuptor (UCD-300) at power 5 (high) for 30 s x 4 times, and centrifuged at 1200 g at 4°C for 25 min. Viral supernatants were then stored at − 80°C. Viral titers were then determined by flow cytometry analysis of GFP-positive cell populations in Vero cells infected with serially diluted BDV vector stocks.
Differentiation of MSCs into adipocytes
Semi-confluent MSCs were cultured for 2 weeks in StemPro Adipogenesis Differentiation Kit (Life Technologies, Grand Island, NY, USA). Generation of adipocytes with lipid droplets was verified by Oil Red O staining. Specifically, differentiated cells were fixed by formalin, followed by fixation of isopropanol (60%) treatment for 5 min and incubation with Oil Red O solution for 10 min. After washing, cells were incubated with hematoxylin for 1 min to counter-stain nuclei, as per the manufacturer's directions.
Spontaneous differentiation
iPSCs were dissociated by Versene (Life Technologies) for 30 min and cultured in the human iPSC medium on low adhesion plates, allowing formation of embryoid bodies. Embryoid bodies were cultured as suspension for 4 days in the iPSC medium, and then cultured in Dulbecco's modified Eagle's medium medium supplemented with 20% FBS for 1 week.
Embryoid bodies were then cultured on Matrigel-coated Lab-Tek Chamber slides in Dulbecco's modified Eagle's medium with 20% FBS for 1 week.
Guided differentiation of iPSCs into definitive endoderm iPSCs cultured on Matrigel-coated plates were treated with 100 ng ml − 1 Activin A (Peprotech, Rocky Hill, NJ, USA) and 25 ng ml − 1 Wnt3a (R&D Systems, Minneapolis, MN, USA) in advanced RPMI (Invitrogen, Waltham, MA, USA) for 1 day, followed by treatment with 100 ng ml − 1 Activin A in advanced RPMI medium supplemented with 0.2% fetal bovine serum for 2 days. Total RNA was isolated with Trizol reagent (Invitrogen), used for real-time reverse transcription-PCR analysis as reported previously. 52 For SOX17-specific primers (5′-ACGCCGAGTTGAGCAAGA-3′ and 5′-TCTGCC TCCTCCACGAAG-3′, with Roche Universal Probe #61) and FOXA2-specific primers (5′-CGTTCCGGGTCTGAACTG-3′ and 5′-ACCGCTCCCAGCATACTT T-3′ with Roche Universal Probe #68) were used to detect SOX17 and FOXA2 transcripts as definitive endoderm markers.
Immunostaining
For immunostaining, cells were cultured in matrigel-coated Lab-Tek Chamber slides (Sigma-Aldrich, St Louis, MO, USA), fixed in 4% paraformaldehyde in phosphate-buffered saline, permeabilized with 0.5% Triton X-100 and blocked in phosphate-buffered saline supplemented with 5% fetal bovine serum. Cells were stained by specific antibodies: SSEA4 and TRA-1-60 (EMD Millipore #SCR001), OCT4 (Cell Signaling Technology, Danvers, MA, USA; #2750), SOX2 (Cell Signaling Technology #2748), FOXA2 (EMD Millipore #07-633), βIII-tubulin (Abcam, Cambridge, MA, USA; # 41489), CD31 (Santa Cruz Biotechnology, Dallas, TX, USA; # SC1506) and cardiac troponin T (Abcam #ab8295).
